|
|
循环肿瘤DNA在肝癌中的临床应用价值及展望
|
Abstract:
肝细胞癌(Hepatocellular carcinoma, HCC)作为最常见的原发性肝癌，也是世界范围内最常见的癌症相关死亡的原因之一。由于HCC潜伏期较长、诊断阶段较晚及对全身治疗不敏感，到目前为止，肝脏活检和手术切除仍是临床决策的金标准。传统活检可提供肿瘤生物学信息，但其侵入性高，样本量少，无法代表肿瘤异质性或监测动态肿瘤进展，因此迫切需要微创或无创的新诊断策略以便早期诊断HCC并监测肿瘤进展。近年来，“液体活检(Liquid biopsy)”的概念引起了广泛关注，其无创、可重复分析的特性可实时监测肿瘤复发、转移或治疗反应。随着高灵敏度液体活检技术的发展，HCC循环肿瘤细胞(circulating tumor cells, CTCs)、循环肿瘤DNA (circulating tumor DNA, ctDNA)以及肿瘤来源的外泌体等检测和分析的发展前景可观。本综述重点介绍ctDNA检测及其作为HCC诊断、预后和监测的无创生物标志物的临床应用及展望。
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and one of the leading causes of cancer-related deaths worldwide. Due to its long latency period, late-stage diagnosis, and insensitivity to systemic therapies, conventional tissue biopsy and surgical resection remain the gold standards for clinical decision-making to date. Although traditional biopsy can provide tumor biology, it is imperative to find non-invasive diagnostic strategy for early detection and monitoring of HCC due to its invasive nature, limited sample size, and inability to represent tumor heterogeneity or monitor dynamic tumor progression. In recent years, a new concept of “liquid biopsy” has emerged with significant attention due to its non-invasive and repeatable analysis capabilities, enabling real-time monitoring of tumor recurrence, metastasis, or treatment response. With advancements in high-sensitivity liquid biopsy technologies, the detection and analysis of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and tumor-derived exosomes in HCC have shown promising prospects. The ctDNA detection and its clinical applications and future potential as a non-invasive biomarker for the diagnosis, prognosis, and monitoring of HCC are highlighted in this review.
| [1] | Dasgupta, P., Henshaw, C., Youlden, D.R., Clark, P.J., Aitken, J.F. and Baade, P.D. (2020) Global Trends in Incidence Rates of Primary Adult Liver Cancers: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 10, Article 171. https://doi.org/10.3389/fonc.2020.00171 |
| [2] | Yang, D., Hanna, D.L., Usher, J., LoCoco, J., Chaudhari, P., Lenz, H., et al. (2014) Impact of Sex on the Survival of Patients with Hepatocellular Carcinoma: A Surveillance, Epidemiology, and End Results Analysis. Cancer, 120, 3707-3716. https://doi.org/10.1002/cncr.28912 |
| [3] | Johnson, P., Zhou, Q., Dao, D.Y. and Lo, Y.M.D. (2022) Circulating Biomarkers in the Diagnosis and Management of Hepatocellular Carcinoma. Nature Reviews Gastroenterology & Hepatology, 19, 670-681. https://doi.org/10.1038/s41575-022-00620-y |
| [4] | Mohammadian, M., Bakeshei, K.A. and Mohammadian-Hafshejani, A. (2020) International Epidemiology of Liver Cancer: Geographical Distribution, Secular Trends and Predicting the Future. Journal of Preventive Medicine and Hygiene, 61, E259-E289. |
| [5] | Ye, Q., Ling, S., Zheng, S. and Xu, X. (2019) Liquid Biopsy in Hepatocellular Carcinoma: Circulating Tumor Cells and Circulating Tumor DNA. Molecular Cancer, 18, Article No. 114. https://doi.org/10.1186/s12943-019-1043-x |
| [6] | Meng, Z., Ren, Q., Zhong, G., Li, S., Chen, Y., Wu, W., et al. (2021) Noninvasive Detection of Hepatocellular Carcinoma with Circulating Tumor DNA Features and α-Fetoprotein. The Journal of Molecular Diagnostics, 23, 1174-1184. https://doi.org/10.1016/j.jmoldx.2021.06.003 |
| [7] | Colombo, F., Baldan, F., Mazzucchelli, S., Martin-Padura, I., Marighetti, P., Cattaneo, A., et al. (2011) Evidence of Distinct Tumour-Propagating Cell Populations with Different Properties in Primary Human Hepatocellular Carcinoma. PLOS ONE, 6, e21369. https://doi.org/10.1371/journal.pone.0021369 |
| [8] | Renzulli, M. and Golfieri, R. (2015) Proposal of a New Diagnostic Algorithm for Hepatocellular Carcinoma Based on the Japanese Guidelines but Adapted to the western World for Patients under Surveillance for Chronic Liver Disease. Journal of Gastroenterology and Hepatology, 31, 69-80. https://doi.org/10.1111/jgh.13150 |
| [9] | Temraz, S., Nasr, R., Mukherji, D., Kreidieh, F. and Shamseddine, A. (2022) Liquid Biopsy Derived Circulating Tumor Cells and Circulating Tumor DNA as Novel Biomarkers in Hepatocellular Carcinoma. Expert Review of Molecular Diagnostics, 22, 507-518. https://doi.org/10.1080/14737159.2022.2094706 |
| [10] | Nakazawa, T., Hidaka, H., Takada, J., Okuwaki, Y., Tanaka, Y., Watanabe, M., et al. (2013) Early Increase in α-Fetoprotein for Predicting Unfavorable Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. European Journal of Gastroenterology & Hepatology, 25, 683-689. https://doi.org/10.1097/meg.0b013e32835d913b |
| [11] | Kudo, A., Matsumura, S., Ban, D., Irie, T., Ochiai, T., Tanaka, S., et al. (2014) Does the Preoperative Alpha-Fetoprotein Predict the Recurrence and Mortality after Hepatectomy for Hepatocellular Carcinoma without Macrovascular Invasion in Patients with Normal Liver Function? Hepatology Research, 44, E437-E446. https://doi.org/10.1111/hepr.12335 |
| [12] | Li, J., Han, X., Yu, X., Xu, Z., Yang, G., Liu, B., et al. (2018) Clinical Applications of Liquid Biopsy as Prognostic and Predictive Biomarkers in Hepatocellular Carcinoma: Circulating Tumor Cells and Circulating Tumor DNA. Journal of Experimental & Clinical Cancer Research, 37, Article No. 213. https://doi.org/10.1186/s13046-018-0893-1 |
| [13] | 杨小周, 张灵强, 王凯强, 等. 循环肿瘤细胞与循环肿瘤DNA在肝细胞癌中的研究进展[J]. 河北医药, 2023, 45(3): 446-450. |
| [14] | 叶婷丹, 雷学忠. 早期肝癌无创诊断之匙——循环游离DNA联合型液体活检[J]. 临床肝胆病杂志, 2022, 38(4): 923-926. |
| [15] | Kustanovich, A., Schwartz, R., Peretz, T. and Grinshpun, A. (2019) Life and Death of Circulating Cell-Free DNA. Cancer Biology & Therapy, 20, 1057-1067. https://doi.org/10.1080/15384047.2019.1598759 |
| [16] | Zhu, G., Liu, W., Tang, Z., Qu, W., Fang, Y., Jiang, X., et al. (2021) Serial Circulating Tumor DNA to Predict Early Recurrence in Patients with Hepatocellular Carcinoma: A Prospective Study. Molecular Oncology, 16, 549-561. https://doi.org/10.1002/1878-0261.13105 |
| [17] | Kopystecka, A., Patryn, R., Leśniewska, M., Budzyńska, J. and Kozioł, I. (2023) The Use of ctDNA in the Diagnosis and Monitoring of Hepatocellular Carcinoma—Literature Review. International Journal of Molecular Sciences, 24, Article 9342. https://doi.org/10.3390/ijms24119342 |
| [18] | Renzulli, M., Pecorelli, A., Brandi, N., Brocchi, S., Tovoli, F., Granito, A., et al. (2022) The Feasibility of Liver Biopsy for Undefined Nodules in Patients under Surveillance for Hepatocellular Carcinoma: Is Biopsy Really a Useful Tool? Journal of Clinical Medicine, 11, Article 4399. https://doi.org/10.3390/jcm11154399 |
| [19] | Krishnamurthy, N., Spencer, E., Torkamani, A. and Nicholson, L. (2017) Liquid Biopsies for Cancer: Coming to a Patient near You. Journal of Clinical Medicine, 6, Article 3. https://doi.org/10.3390/jcm6010003 |
| [20] | Freitas, A.J.A.D., Causin, R.L., Varuzza, M.B., et al. (2022) Liquid Biopsy as a Tool for the Diagnosis, Treatment, and Monitoring of Breast Cancer. International Journal of Molecular Sciences, 23, 9952. https://doi.org/10.3390/ijms23179952 |
| [21] | Crowley, E., Di Nicolantonio, F., Loupakis, F. and Bardelli, A. (2013) Liquid Biopsy: Monitoring Cancer-Genetics in the Blood. Nature Reviews Clinical Oncology, 10, 472-484. |
| [22] | 李少平, 王迪, 杨若巍, 等. 液体活检在肿瘤诊疗全程管理中的现状及展望[J]. 中国临床研究, 2024, 37(6): 959-964. |
| [23] | Ding, Y., Yao, J., Wen, M., Liu, X., Huang, J., Zhang, M., et al. (2022) The Potential, Analysis and Prospect of ctDNA Sequencing in Hepatocellular Carcinoma. PeerJ, 10, e13473. https://doi.org/10.7717/peerj.13473 |
| [24] | Luo, H., Wei, W., Ye, Z., Zheng, J. and Xu, R. (2021) Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Trends in Molecular Medicine, 27, 482-500. https://doi.org/10.1016/j.molmed.2020.12.011 |
| [25] | Pons-Belda, O.D., Fernandez-Uriarte, A. and Diamandis, E.P. (2021) Can Circulating Tumor DNA Support a Successful Screening Test for Early Cancer Detection? The Grail Paradigm. Diagnostics, 11, Article 2171. https://doi.org/10.3390/diagnostics11122171 |
| [26] | Fiala, C. and Diamandis, E.P. (2018) Utility of Circulating Tumor DNA in Cancer Diagnostics with Emphasis on Early Detection. BMC Medicine, 16, Article No. 166. https://doi.org/10.1186/s12916-018-1157-9 |
| [27] | Ungerer, V., Bronkhorst, A.J. and Holdenrieder, S. (2020) Preanalytical Variables That Affect the Outcome of Cell-Free DNA Measurements. Critical Reviews in Clinical Laboratory Sciences, 57, 484-507. https://doi.org/10.1080/10408363.2020.1750558 |
| [28] | Yuwono, N.L., Warton, K. and Ford, C.E. (2021) The Influence of Biological and Lifestyle Factors on Circulating Cell-Free DNA in Blood Plasma. eLife, 10, e69679. https://doi.org/10.7554/elife.69679 |
| [29] | 梁人山, 张育, 陈祖涛, 等. 液体活检在肝癌中的研究进展[J]. 肝癌电子杂志, 2024, 11(1): 30-33. |
| [30] | Ikeda, S., Lim, J.S. and Kurzrock, R. (2018) Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics. Molecular Cancer Therapeutics, 17, 1114-1122. https://doi.org/10.1158/1535-7163.mct-17-0604 |
| [31] | Gao, Y., Zhao, H., An, K., Liu, Z., Hai, L., Li, R., et al. (2022) Whole-Genome Bisulfite Sequencing Analysis of Circulating Tumour DNA for the Detection and Molecular Classification of Cancer. Clinical and Translational Medicine, 12, e1014. https://doi.org/10.1002/ctm2.1014 |
| [32] | Mody, K., Kasi, P.M., Yang, J.D., Surapaneni, P.K., Ritter, A., Roberts, A., et al. (2019) Feasibility of Circulating Tumor DNA Testing in Hepatocellular Carcinoma. Journal of Gastrointestinal Oncology, 10, 745-750. https://doi.org/10.21037/jgo.2019.02.10 |
| [33] | Keppens, C., Palma, J.F., Das, P.M., Scudder, S., Wen, W., Normanno, N., et al. (2018) Detection of EGFR Variants in Plasma. The Journal of Molecular Diagnostics, 20, 483-494. https://doi.org/10.1016/j.jmoldx.2018.03.006 |
| [34] | Postel, M., Roosen, A., Laurent-Puig, P., Taly, V. and Wang-Renault, S. (2017) Droplet-Based Digital PCR and Next Generation Sequencing for Monitoring Circulating Tumor DNA: A Cancer Diagnostic Perspective. Expert Review of Molecular Diagnostics, 18, 7-17. https://doi.org/10.1080/14737159.2018.1400384 |
| [35] | Diehl, F., Schmidt, K., Durkee, K.H., Moore, K.J., Goodman, S.N., Shuber, A.P., et al. (2008) Analysis of Mutations in DNA Isolated from Plasma and Stool of Colorectal Cancer Patients. Gastroenterology, 135, 489-498.E7. https://doi.org/10.1053/j.gastro.2008.05.039 |
| [36] | Lanman, R.B., Mortimer, S.A., Zill, O.A., Sebisanovic, D., Lopez, R., Blau, S., et al. (2015) Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. PLOS ONE, 10, e0140712. https://doi.org/10.1371/journal.pone.0140712 |
| [37] | Mastoraki, S., Strati, A., Tzanikou, E., Chimonidou, M., Politaki, E., Voutsina, A., et al. (2018) ESR1 Methylation: A Liquid Biopsy-Based Epigenetic Assay for the Follow-Up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment. Clinical Cancer Research, 24, 1500-1510. https://doi.org/10.1158/1078-0432.ccr-17-1181 |
| [38] | Cheng, T.H.T., Jiang, P., Tam, J.C.W., Sun, X., Lee, W., Yu, S.C.Y., et al. (2017) Genomewide Bisulfite Sequencing Reveals the Origin and Time-Dependent Fragmentation of Urinary cfDNA. Clinical Biochemistry, 50, 496-501. https://doi.org/10.1016/j.clinbiochem.2017.02.017 |
| [39] | Wang, J., Huang, A., Wang, Y., Yin, Y., Fu, P., Zhang, X., et al. (2020) Circulating Tumor DNA Correlates with Microvascular Invasion and Predicts Tumor Recurrence of Hepatocellular Carcinoma. Annals of Translational Medicine, 8, 237-237. https://doi.org/10.21037/atm.2019.12.154 |
| [40] | Zhang, Y., Wu, H., Shen, J., Ahsan, H., Tsai, W.Y., Yang, H., et al. (2007) Predicting Hepatocellular Carcinoma by Detection of Aberrant Promoter Methylation in Serum DNA. Clinical Cancer Research, 13, 2378-2384. https://doi.org/10.1158/1078-0432.ccr-06-1900 |
| [41] | Bai, Y., Shen, Y., Yuan, Q., Lv, C. and Xing, Q. (2019) Evaluation of Relationship between Occurrence of Liver Cancer and Methylation of Fragile Histidine Triad (FHIT) and P16 Genes. Medical Science Monitor, 25, 1301-1306. https://doi.org/10.12659/msm.912315 |
| [42] | Lin, Q., Chen, L., Tang, Y. and Wang, J. (2005) Promoter Hypermethylation of P16 Gene and DAPK Gene in Sera from Hepatocellular Carcinoma (HCC) Patients. Chinese Journal of Cancer Research, 17, 250-254. https://doi.org/10.1007/s11670-005-0020-7 |
| [43] | Huang, Z., Hu, Y., Hua, D., Wu, Y., Song, M. and Cheng, Z. (2011) Quantitative Analysis of Multiple Methylated Genes in Plasma for the Diagnosis and Prognosis of Hepatocellular Carcinoma. Experimental and Molecular Pathology, 91, 702-707. https://doi.org/10.1016/j.yexmp.2011.08.004 |
| [44] | Iizuka, N., Oka, M., Sakaida, I., Moribe, T., Miura, T., Kimura, N., et al. (2011) Efficient Detection of Hepatocellular Carcinoma by a Hybrid Blood Test of Epigenetic and Classical Protein Markers. Clinica Chimica Acta, 412, 152-158. https://doi.org/10.1016/j.cca.2010.09.028 |
| [45] | Huang, G., Krocker, J.D., Kirk, J.L., Merwat, S.N., Ju, H., Soloway, R.D., et al. (2014) Evaluation of INK4A Promoter Methylation Using Pyrosequencing and Circulating Cell-Free DNA from Patients with Hepatocellular Carcinoma. Clinical Chemistry and Laboratory Medicine (CCLM), 52, 899-909. https://doi.org/10.1515/cclm-2013-0885 |
| [46] | Sun, F., Fan, Y., Zhao, J., Zhang, F., Gao, S., Zhao, Z., et al. (2012) Detection of TFPI2 Methylation in the Serum of Hepatocellular Carcinoma Patients. Digestive Diseases and Sciences, 58, 1010-1015. https://doi.org/10.1007/s10620-012-2462-3 |
| [47] | Dong, X., Hou, Q., Chen, Y. and Wang, X. (2017) Diagnostic Value of the Methylation of Multiple Gene Promoters in Serum in Hepatitis B Virus-Related Hepatocellular Carcinoma. Disease Markers, 2017, Article 2929381. https://doi.org/10.1155/2017/2929381 |
| [48] | Pasha, H.F., Mohamed, R.H. and Radwan, M.I. (2019) RASSF1A and SOCS1 Genes Methylation Status as a Noninvasive Marker for Hepatocellular Carcinoma. Cancer Biomarkers, 24, 241-247. |
| [49] | Mohamed, N.A., Swify, E.M., Amin, N.F., Soliman, M.M., Tag-Eldin, L.M. and Elsherbiny, N.M. (2012) Is Serum Level of Methylated RASSF1A Valuable in Diagnosing Hepatocellular Carcinoma in Patients with Chronic Viral Hepatitis C? Arab Journal of Gastroenterology, 13, 111-115. https://doi.org/10.1016/j.ajg.2012.06.009 |
| [50] | Xu, R., Wei, W., Krawczyk, M., Wang, W., Luo, H., Flagg, K., et al. (2017) Circulating Tumour DNA Methylation Markers for Diagnosis and Prognosis of Hepatocellular Carcinoma. Nature Materials, 16, 1155-1161. https://doi.org/10.1038/nmat4997 |
| [51] | Cai, J., Chen, L., Zhang, Z., Zhang, X., Lu, X., Liu, W., et al. (2019) Genome-Wide Mapping of 5-Hydroxymethylcytosines in Circulating Cell-Free DNA as a Non-Invasive Approach for Early Detection of Hepatocellular Carcinoma. Gut, 68, 2195-2205. https://doi.org/10.1136/gutjnl-2019-318882 |
| [52] | Cai, Z., Chen, G., Zeng, Y., Dong, X., Li, Z., Huang, Y., et al. (2019) Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma. Clinical Cancer Research, 25, 5284-5294. https://doi.org/10.1158/1078-0432.ccr-18-3477 |
| [53] | Cai, Z., Chen, G., Zeng, Y., Dong, X., Lin, M., Huang, X., et al. (2017) Circulating Tumor DNA Profiling Reveals Clonal Evolution and Real-Time Disease Progression in Advanced Hepatocellular Carcinoma. International Journal of Cancer, 141, 977-985. https://doi.org/10.1002/ijc.30798 |
| [54] | Yang, J.D., Hainaut, P., Gores, G.J., Amadou, A., Plymoth, A. and Roberts, L.R. (2019) A Global View of Hepatocellular Carcinoma: Trends, Risk, Prevention and Management. Nature Reviews Gastroenterology & Hepatology, 16, 589-604. https://doi.org/10.1038/s41575-019-0186-y |
| [55] | Matsumae, T., Kodama, T., Myojin, Y., Maesaka, K., Sakamori, R., Takuwa, A., et al. (2022) Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy. Cancers, 14, Article 3367. https://doi.org/10.3390/cancers14143367 |
| [56] | Li, Y., Zheng, Y., Wu, L., Li, J., Ji, J., Yu, Q., et al. (2021) Current Status of ctDNA in Precision Oncology for Hepatocellular Carcinoma. Journal of Experimental & Clinical Cancer Research, 40, Article No. 140. https://doi.org/10.1186/s13046-021-01940-8 |
| [57] | Tzartzeva, K., Obi, J., Rich, N.E., Parikh, N.D., Marrero, J.A., Yopp, A., et al. (2018) Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis: A Meta-Analysis. Gastroenterology, 154, 1706-1718.e1. https://doi.org/10.1053/j.gastro.2018.01.064 |
| [58] | Oversoe, S.K., Clement, M.S., Pedersen, M.H., Weber, B., Aagaard, N.K., Villadsen, G.E., et al. (2020) TERT Promoter Mutated Circulating Tumor DNA as a Biomarker for Prognosis in Hepatocellular Carcinoma. Scandinavian Journal of Gastroenterology, 55, 1433-1440. https://doi.org/10.1080/00365521.2020.1837928 |
| [59] | Jiao, J., Watt, G.P., Stevenson, H.L., Calderone, T.L., Fisher‐Hoch, S.P., Ye, Y., et al. (2018) Telomerase Reverse Transcriptase Mutations in Plasma DNA in Patients with Hepatocellular Carcinoma or Cirrhosis: Prevalence and Risk Factors. Hepatology Communications, 2, 718-731. https://doi.org/10.1002/hep4.1187 |
| [60] | Yan, L., Chen, Y., Zhou, J., Zhao, H., Zhang, H. and Wang, G. (2018) Diagnostic Value of Circulating Cell-Free DNA Levels for Hepatocellular Carcinoma. International Journal of Infectious Diseases, 67, 92-97. https://doi.org/10.1016/j.ijid.2017.12.002 |
| [61] | 顾心怡, 李贺明, 王喆, 等. 液体活检在消化道肿瘤诊疗中应用的研究现状[J]. 大连医科大学学报, 2020, 42(1): 76-80. |
